# ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

> **NCT01592045** · PHASE1,PHASE2 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 28 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** ch14.18 -NCI
- **BIOLOGICAL:** ch14.18-UTC
- **BIOLOGICAL:** Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- **BIOLOGICAL:** Aldesleukin (IL-2)
- **DRUG:** Isotretinoin

## Key facts

- **NCT ID:** NCT01592045
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2015-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01592045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01592045, "ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01592045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*